Clinical Research Directory

Inclusion Criteria: Group A: CI 1- Age \> 18 years AND CI2a- Person eligible for screening with a nodule or lung mass with no indication of reassessment by CT scan before the next round of screening, as recommended by the multidisciplinary consultation meeting OR CI2b- Person not eligible for screening with a nodule or lung mass with an indication for reassessment by CT scan without immediate diagnostic workup (PET scan, biopsy, surgery) as determined by the multidisciplinary consultation meeting. Group B CI1- Age \> 18 years AND CI2- Indication for biopsy or surgical excision for diagnostic and therapeutic purposes proposed in a multidisciplinary consultation meeting. Group C CI1a- Age 40 - 75 and daily smoking for at least 20 years initiated before age 15 OR CI1b- Age 50 - 75 and passive smoking for at least 20 years in a closed environment (family or workplace) OR CI1c- Age 50 - 75 and smoking 10 cig/d for 30 years or 15 cig/d for 25 years or 20 pack-years with no withdrawal period OR CI1d- Age 50 - 75 and daily smoking for at least 10 years combined with at least one other lung cancer risk factor from among : * Self-reported daily passive smoking for \> 10 years (smokers at home or in enclosed environments) * Self-reported exposure to a lung carcinogen: Radon, coal smoke, soot, diesel, nickel, beryllium, arsenic, cadmium, asbestos * 1st-degree family history of lung cancer * Personal history of tobacco-related disease, including atheromatous cardiovascular disease, COPD or emphysema, cancer not monitored by chest imaging * weekly use of cannabis (joints) for 10 years All Groups: * Have signed an informed consent form * Affiliated with or benefiting from a social security scheme * Male or female Exclusion Criteria: Goups A and B Contraindication to lung biopsy or thoracic surgery for diagnostic or therapeutic purposes Group C Eligible for lung cancer screening according to INCa\* criteria * Previous cancer \< 5 years (except carcinoma in situ of the uterine cervix, basal cell carcinoma of the skin, non-invasive urothelial carcinoma treated for curative purposes without CT lung surveillance, prostate cancer with undiagnosable PSA) * Symptoms of lung cancer (involuntary weight loss \> 10% of usual weight in 1 year, hemoptysis) * Known history of pulmonary nodule requiring specialized follow-up * History of pulmonary fibrosis or pulmonary hypertension * Active pulmonary parenchymal infection * Severe cardiac or respiratory insufficiency (rest dyspnea) * Performance status (WHO) 2, 3 or 4 All Groups * patient privé de liberté * patient sous tutelle ou curatelle * femmes enceintes ou allaitantes * patient dans l'incapacité d'effectuer le suivi de 30 mois